profit from every $100 of sales.
$0$100
Avanos Medical
We have no price for Avanos Medical since 24 July 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$24.99+0.04% today
+130.5% since Oct 13, 25
1-year low $10.661-year high $25.05
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Avanos Medical sold, what it kept, and what it did with the cash.
Sales went from $684 million in 2022 to $701 million in 2025, with -$72.9 million of profit last year.
SalesProfit
Avanos Medical handed back 8% of the cash it generated last year.
Buybacks $3M
Free cash flow 2025$43M
Bought back its own shares$3M
Paid as dividends–
Cash vs. debt$90M vs. $129M
Avanos Medical vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Avanos Medical | No profit yet | ||
 Boston Scientific | 22.2× · Fair price | ||
 Koninklijke Philips | 30.1× · Expensive | ||
 Steris | 32.8× · Expensive | ||
 Zimmer Biomet Holdings | 27.7× · Fair price |
AI analysis
An AI analyst reads Avanos Medical's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 684 | 673 | 688 | 701 | |
| 394 | 380 | 381 | 354 | |
| 36 | 4 | 41 | 15 | |
| 84 | 53 | -346 | -20 | |
| 51 | -62 | -392 | -73 | |
| 1.07 | -1.32 | -8.53 | -1.57 | |
| 57.6% | 56.4% | 55.4% | 50.5% | |
| 5.2% | 0.6% | 5.9% | 2.2% | |
| 7.4% | -9.2% | -57.0% | -10.4% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,787 | 1,692 | 1,154 | 1,074 |
| Cash | 128 | 88 | 108 | 90 |
| Total debt | 277 | 209 | 170 | 129 |
| Total liabilities | 496 | 456 | 326 | 296 |
| 1,291 | 1,236 | 829 | 778 | |
| 47 | 47 | 46 | 46 | |
| 1.8% | 0.4% | -30.9% | -5.1% | |
| 3.9% | -5.0% | -47.3% | -9.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 91 | 32 | 101 | 75 | |
| 19 | 18 | 18 | 32 | |
| 72 | 15 | 83 | 43 | |
| Dividends paid | – | – | – | – |
| 46 | 19 | 13 | 3 | |
| 16 | 16 | 14 | 13 |
Valuation
- –
- 25.0×
- –
- 1.5×
- 1.7×
- 27.2×
- –
- 3.7%
- -6.2%
- 0.0%
Profitability
- 50.5%
- 2.2%
- -10.4%
- -2.6%
- -6.0%
- -9.5%
- -8.9%
- -6.6%
- -6.2%
- 3.2%
Growth
- +0.8%
- –
- −48.0%
- –
- −0.9%
Financial health
- –
- 0.18
- 13.2%
- -7.9×
- 2.48
- 1.40
- 0.68
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 25%of 963
Bottom 28%of 894
Bottom 19%of 908
Top 32%of 991
What analysts expect
- Average price target
- $23.00
- Range
- $20.00 – $26.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | 0.22 | 0.16 | +37.5% |
| Feb 24, 2026 | 0.29 | 0.24 | +20.8% |
| Nov 5, 2025 | 0.22 | 0.12 | +83.3% |
| Aug 5, 2025 | 0.17 | 0.18 | −5.6% |
| May 6, 2025 | 0.26 | 0.19 | +36.8% |
| Feb 26, 2025 | 0.43 | 0.40 | +7.5% |
| Oct 30, 2024 | 0.36 | 0.36 | +0.0% |
| Jul 31, 2024 | 0.34 | 0.29 | +17.2% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
25No pass
Benjamin Graham
55No pass
Philip Fisher
30No pass
Peter Lynch
28No pass
Joel Greenblatt
0No pass
Charlie Munger
32No pass
Terry Smith
25No pass
Questions about Avanos Medical
Is Avanos Medical a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Avanos Medical AI analysis
What does Avanos Medical do?
Avanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It is in Medical - Devices.
Does Avanos Medical pay a dividend?
No. Avanos Medical does not pay a dividend at the moment; in 2025 it returned $3.30 million to shareholders by buying back its own shares.
Is Avanos Medical stock halal?
Yes. Avanos Medical passes our halal screen: its business is permitted and its debt is 11% of its market value, under the 30% limit. How we check
Who are Avanos Medical's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with Avanos Medical's.
Prices: daily closes to Jul 24, 2026. Fundamentals: company reports via invest-like data.